Emergent BioSolutions | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.13B 55.39M 2025-03
ALKERMES USD 2.08B 26.41M 2025-03
Alnylam Pharmaceuticals USD 4.21B 26.17M 2025-03
Amarin USD 655.68M 29.67M 2025-03
ANI Pharmaceuticals USD 1.29B 8.73M 2025-03
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Exact Sciences USD 5.71B 217.07M 2025-03
Exelixis USD 2.84B 110.44M 2025-04
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Ionis Pharmaceuticals USD 2.81B 190.73M 2025-03
Ironwood Pharmaceuticals USD 351.3M 38.22M 2024-12
Lonza CHF 19.73B 1.85B 2024-12
Merck USD 115.12B 1.98B 2025-03
Moderna USD 12.7B 1.44B 2025-03
Myriad Genetics USD 1.01B 21.5M 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Pacira USD 1.59B 33.15M 2025-03
Pfizer USD 208.03B 5.37B 2025-03
PTC Therapeutics USD 2.66B 950.36M 2025-03
Sanofi 131.89B 906M 2025-03
Sarepta Therapeutics USD 3.47B 497.79M 2025-03
United Therapeutics USD 7.74B 379.9M 2025-03


Emergent BioSolutions Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Jul 2025.